TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

PEMETREXED DISODIUM

PEMETREXED DISODIUM
Oncology Approved 2022-05-25
10
Indications
--
Phase 3 Trials
3
Years on Market

PEMETREXED DISODIUM Approval History

Loading approval history...

What PEMETREXED DISODIUM Treats

2 indications

PEMETREXED DISODIUM is approved for 2 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Non-Small Cell Lung Cancer
  • Malignant Pleural Mesothelioma
Source: FDA Label

Drugs Similar to PEMETREXED DISODIUM

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ALIMTA
PEMETREXED
2 shared
Eli Lilly
Shared indications:
Non-Small Cell Lung CancerMalignant Pleural Mesothelioma
AXTLE
PEMETREXED DIPOTASSIUM
2 shared
AVYXA HOLDINGS
Shared indications:
Non-Small Cell Lung CancerMalignant Pleural Mesothelioma
PEMETREXED
PEMETREXED DISODIUM
2 shared
SHILPA
Shared indications:
Non-Small Cell Lung CancerMalignant Pleural Mesothelioma
PEMETREXED FOR INJECTION
PEMETREXED
2 shared
Dr. Reddy's
Shared indications:
Non-Small Cell Lung CancerMalignant Pleural Mesothelioma
PEMFEXY
PEMETREXED
2 shared
EAGLE PHARMS
Shared indications:
Non-Small Cell Lung CancerMalignant Pleural Mesothelioma
ALECENSA
ALECTINIB HYDROCHLORIDE
1 shared
Roche
Shared indications:
Non-Small Cell Lung Cancer
ALUNBRIG
BRIGATINIB
1 shared
Takeda
Shared indications:
Non-Small Cell Lung Cancer
ALYMSYS
BEVACIZUMAB-MALY
1 shared
AMNEAL PHARMS LLC
Shared indications:
Non-Small Cell Lung Cancer
AUGTYRO
REPOTRECTINIB
1 shared
Bristol-Myers Squibb
Shared indications:
Non-Small Cell Lung Cancer
AVGEMSI
GEMCITABINE HYDROCHLORIDE
1 shared
AVYXA HOLDINGS
Shared indications:
Non-Small Cell Lung Cancer
AVZIVI
BEVACIZUMAB-TNJN
1 shared
BIO-THERA SOLUTIONS LTD
Shared indications:
Non-Small Cell Lung Cancer
BEIZRAY
DOCETAXEL
1 shared
ZHUHAI
Shared indications:
Non-Small Cell Lung Cancer
BIZENGRI
ZENOCUTUZUMAB-ZBCO
1 shared
MERUS N.V.
Shared indications:
Non-Small Cell Lung Cancer
CYRAMZA
RAMUCIRUMAB
1 shared
Eli Lilly
Shared indications:
Non-Small Cell Lung Cancer
DATROWAY
DATOPOTAMAB DERUXTECAN-DLNK
1 shared
DAIICHI SANKYO INC
Shared indications:
Non-Small Cell Lung Cancer
DOCIVYX
DOCETAXEL
1 shared
AVYXA HOLDINGS
Shared indications:
Non-Small Cell Lung Cancer
EMRELIS
TELISOTUZUMAB VEDOTIN-TLLV
1 shared
AbbVie
Shared indications:
Non-Small Cell Lung Cancer
ENSACOVE
ENSARTINIB HYDROCHLORIDE
1 shared
XCOVERY
Shared indications:
Non-Small Cell Lung Cancer
ERLOTINIB HYDROCHLORIDE
ERLOTINIB HYDROCHLORIDE
1 shared
MSN
Shared indications:
Non-Small Cell Lung Cancer
GEFITINIB
GEFITINIB
1 shared
Cipla
Shared indications:
Non-Small Cell Lung Cancer
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PEMETREXED DISODIUM FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Pemetrexed for injection is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC),with no EGFR or ALK genomic tumor aberrations. in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous (NSCLC) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based firs...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.